Treatment of diabetic foot infection: An open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy

International Journal of Antimicrobial Agents

Volumn 7, Issue 2, 1996, Pages 143-147

  Bouter, K Paul ^a   Visseren, Frank L J ^b   Van Loenhout, Ruud M M ^a   Bartelink, Anton K M ^b   Erkelens, D Willem ^c   Diepersloot, Rob J A ^d  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b EEMLAND HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Antibiotic therapy; Clinical trial; Diabetic foot

Indexed keywords

CILASTATIN; CLINDAMYCIN; IMIPENEM; PIPERACILLIN;

AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC FOOT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0030199354     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-8579(96)00305-6     Document Type: Article

References (20)

1. [1] Calhoun JH, Cantrell J, Cobos J, Lacy J, Valdez RR, Hokanson J, Mader JT. Treatment of diabetic foot infections: Wagner classification therapy and outcome. Foot and Ankle 1988;9:101-106.
2. [2] Evan SL, Nixon BP, Lee I, Yee D, Mooradian AD. Prevalence and nature of podiatric problems in elderly diabetic patients. J Am Geriatr Soc 1991;39:241-245.
3. [3] Shuman CR. Foot disorders in diabetics. Source of serious morbidity. Postgrad Med 1989;74:109-113.
4. [4] Lindegard P, Jonsson B, Lithner F. Amputations in diabetic patients in Gotland and Umea Countries 1971-1980. Acta Med Scand 1984;Suppl 687:89-93.
5. [5] Worth CT, McEwen J. A follow-up study of diabetic patients with foot problems in Nottingham 1971-1978. Practitioner 1982;226:2085-2091.
6. [6] Bouter KP, Storm AJ, de Groot RRM, Uitslager R, Erkelens DW, Diepersloot RJA. The Diabetic foot in Dutch hospitals: epidemiological features and clinical outcome. Eur J Med 1993;2:215-218.
7. [7] Sapico FL, Witte JL, Canawat HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984;6 Suppl 1:8171-176.
8. [8] Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler T, Fineberg N, Norton J. Diabetic foot infections: bacteriologic analysis. Arch Intern Med 1986;146:1935-1940.
9. [9] Hunt JA. Foot infections in diabetics are rarely due to a single microorganism. Diabetic Med 1992;9:749-752.
10. [10] Asfar SK, Al-Arouj M, Al-Nakhi A, Baraka A, Juma T, Johny M. Foot infections in diabetics: the antibiotic choice. Can J Surg 1993;36:170-172.
11. [11] Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. New Engl J Med 1994;331:854-860.
12. [12] Pankey GA. Diagnosis and treatment of skin and soft tissue infections: clinical experience with ticarcillin disodium-clavulanate potassium. Pharmacotherapy 1991;11:905-985.
13. [13] Sesin GP, Paszko A, O'Keefe E. Oral clindamycin and ciprofloxacin therapy for diabetic foot infections. Pharmacotherapy 1990;10:154-156.
14. [14] Calandra GB, Raupp W, Brown KR. Imipenem/cilastatin treatment of lower extremity skin and soft tissue infections in diabetics. Scand J Infect Dis 1987;Suppl 52:15-19.
15. [15] Hughes CE, Johnson CC, Bamberger DM, Reinhardt JF, Peterson LR, Mulligan ME, Gerding DN, George WL, Finegald SM. Treatment and long-term follow-up of foot infections in patients with diabetes or ischemia: a randomised, prospective, double-blind comparison of cefoxitin and ceftizoxime. Clin Therapeut 1987:10 Suppl A:36-49.
16. [16] Jaresko GS, Barrievie SL. Imipenem monotherapy versus combination therapy in the management of mixed bacterial infection: a critical appraisal. Pharmacotherapy 1988;8:324-333.
17. [17] Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. CID 1994;18:683-693.
18. [18] Storm AJ, Bouter KP, Diepersloot RJA, Banga JD, Beerens RG, Erkelens DW. Tissue concentrations of an orally administered antibiotic in diabetic patients with foot infections. J Antimicrob Chemother 1994;34:449-451.
19. [19] Steed DL, Gosten JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized, prospective double blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992;15:1598-1604.
20. [20] Bryson HM, Brogden HM. Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-535.